What we do Sai Life Sciences is an innovator-focused CRDMO offering end-to-end drug discovery, development, and manufacturing services to global pharma and biotech firms. |
Founded in 1,999 |
Market share A leading integrated CRDMO in India with global clientele including 18 of top 25 pharma companies, recognized for quality and innovation. |
Problem solved Supports pharmaceutical innovators by accelerating drug discovery and manufacturing, managing complex modalities like peptides and ADCs efficiently. |
Top clients or who we serve Serves 300+ global clients including major pharma and biotech firms in US, UK, EU, Japan; both B2B and integrated service provider. |
Key management Krishnam Raju Kanumuri (MD & CEO), Dr. Ranga Raju Kanumuri (Whole-time Director), Sivaramakrishnan Chittor (Whole-time Director & CFO). |
Our journey and innovations Founded 1999, expanded from medicinal chemistry to full CRDMO, global presence in US/UK, continuous capacity additions, adoption of AI and new modalities. |
Where we operate Operations and clients across India, USA (Boston), UK (Manchester), and Germany, serving global pharmaceutical innovators. |
Top products or what we offer Discovery services, process R&D, analytical development, formulation, clinical supplies, API manufacturing, specializing in small molecules, peptides, and ADCs. |
Top brands Sai Nxt initiative transforming capabilities; recognized for high-potency API manufacturing, peptide research, and integrated discovery-to-manufacturing. |
Raw materials needed Chemical reagents for medicinal chemistry, raw materials for API synthesis including peptides and oligonucleotides precursors. |
Raw materials supplier Supplies sourced globally from specialized chemical providers; details not publicly disclosed. |
Recurring vs cyclical contribution Revenue is mostly recurring based on ongoing contracts with pharma clients across discovery, development, and manufacturing phases. |
Our industry position Among top Indian CRDMOs, noted for regulatory compliances (USFDA, PMDA), strong technology adoption, and expanding capacity. |
Financial highlights FY25 consolidated revenue approx. ₹1694 Crore with net profit ₹170 Crore; 15-20% revenue CAGR and margin expansion in recent years. |
Geographical revenue split Majority of revenue (~99%) is from outside India, servicing international pharmaceutical companies. |
Order book Strong order pipeline across discovery and manufacturing with 160+ active programs, including 30+ commercial molecules. |
Whats driving growth Growth driven by strategic pharma partnerships, capacity expansions, adoption of AI, and focus on novel drug modalities. |
Our future plans Investing ₹700 Crore in FY26 to expand manufacturing capacity to 1,150 KL and build new process R&D facilities by 2026. |
Our green promise Committed to sustainability with ISO 14001, zero liquid discharge, renewable energy adoption, SBTi targets, and EcoVadis silver rating. |
Our people and values Employs over 3,400 staff globally, fostering innovation culture with emphasis on training, diversity, and high ethical standards. |
Key challenges ahead Navigating competitive CRDMO landscape, managing regulatory and operational risks, and scaling efficiently without quality compromise. |
Interesting facts 100% successful regulatory inspections, first Indian pharma CRDMO joining global sustainability initiatives, and extensive AI integration. |
Risks and strategy Risks include client concentration and regulatory changes; mitigated via diversification, investments in tech and compliance adherence. |
